Search Results

PROTECT I Data Support Abiomed's Impella 2.5

CE Mark Approval Data Published for Essential Medical's Manta Large-Bore Vascular Closure Device

April 3, 2017—Essential Medical, Inc. announced the publication of the CE Mark approval study of the Manta vascular closure device, "Percutaneous Plug-Based Arteriotomy Closure Device for Large-Bore Access" by Nicolas M. Van Mieghem, MD, et al in Journal of the American College of Cardiology: Cardiovascular Interventions.

Report Published of First-In-Human Transcatheter Tricuspid Repair With Mitralign System

March 12, 2015—Mitralign Inc. announced that a detailed reporting of the first successful case of a direct transcatheter tricuspid repair (TTVR) for severe tricuspid regurgitation (TR) has been published online ahead of print by Prof.

Presentation of Abiomed's Impella Quality Assurance Program Highlights Importance of Treatment Protocols

March 19, 2017—Abiomed announced that data from the company's Impella Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry were presented as featured clinical research at the American College of Cardiology's (ACC) 66th annual scientific session in Washington, DC.

Abiomed Impella–Supported PCI in High-Risk Patients Studied in Restore EF

August 16, 2022—Abiomed announced that results of the Restore EF study demonstrated that high-risk percutaneous coronary interventions (PCI) supported by the company’s Impella heart pumps led to significant improvements in left ventricular ejection fraction (LVEF), angina symptoms, and heart failure symptoms at follow-up.

JETSTENT Demonstrates Benefit of Rheolytic Thrombectomy

March 16, 2010—The American College of Cardiology (ACC) announced that findings from the JETSTENT study demonstrated that conducting rheolytic thrombectomy before direct infarct-related artery stenting in patients with acute ST-segment elevation myocardial infarctions (STEMI) produced better clinical results than performing direct stenting alone.

JETSTENT Study Demonstrates Benefit of Rheolytic Thrombectomy Before Stenting in STEMI Patients

March 16, 2010—The American College of Cardiology (ACC) announced that findings from the JETSTENT study demonstrated that conducting rheolytic thrombectomy before direct infarct-related artery stenting in patients with acute ST-segment elevation myocardial infarctions (STEMI) produced better clinical results than performing direct stenting alone.

PROTECT III Evaluates Abiomed’s Impella Placement Before High-Risk PCI

May 19, 2020—Abiomed announced that data from more than 1,000 patients demonstrated that the company’s Impella device reduces in-hospital mortality when placed before a nonemergent percutaneous coronary intervention (PCI) is performed.

Interim Analysis Presented From PROTECT III Study of Abiomed’s Impella Device in High-Risk PCI Patients

October 15, 2020—Abiomed announced that new data from an interim analysis of the PROTECT III study demonstrate reduced rates of major adverse cardiac and cerebrovascular events (MACCEs; a composite of death, stroke, myocardial infarction, and repeat procedures) when the company’s Impella device is used to achieve more complete revascularization in a single setting for high-risk percutaneous coronary intervention (PCI) patients.

FDA Approves Abiomed’s RECOVER IV RCT With Exception From Informed Consent

September 16, 2022—Abiomed announced two FDA approvals related to clinical research of the company’s Impella heart pump in acute myocardial infarction (AMI) cardiogenic shock patients.

Abiomed Begins PROTECT IV RCT of Impella in High-Risk PCI

April 15, 2021—Abiomed announced that the first patient has been enrolled in the PROTECT IV study of the company’s Impella device.